Preetam Shah Net Worth

The estimated Net Worth of Preetam Shah is at least $733 mil dollars as of 11 March 2024. Preetam Shah owns over 18,931 units of Brainstorm Cell Therapeutics stock worth over $63,619 and over the last 5 years he sold BCLI stock worth over $22,855. In addition, he makes $646,892 as Chief Financial Officer, Executive Vice President, e Treasurer at Brainstorm Cell Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Preetam Shah BCLI stock SEC Form 4 insiders trading

Preetam has made over 5 trades of the Brainstorm Cell Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 18,931 units of BCLI stock worth $12,684 on 11 March 2024.

The largest trade he's ever made was exercising 50,000 units of Brainstorm Cell Therapeutics stock on 15 September 2022 worth over $14,000. On average, Preetam trades about 9,744 units every 140 days since 2019. As of 11 March 2024 he still owns at least 227,210 units of Brainstorm Cell Therapeutics stock.

You can see the complete history of Preetam Shah stock trades at the bottom of the page.

Preetam Shah biography

Dr. Preetam Shah Ph.D. serves as Chief Financial Officer, Executive Vice President, Treasurer of the Company. He served as Director, Healthcare Investment Banking at Barclays Capital Plc. since June 2016. He has also served as Vice President, Healthcare Investment Banking at Canaccord Genuity Inc. from 2013 to 2016. Dr. Shah founded Saisarva LLC. and was a financial consultant from 2010-2013 for healthcare-focused private equity firms, hedge funds, and global pharmaceutical companies. From 2006-2009, Dr. Shah served as Vice President, U.S. Operations and Investments at Reliance Capital USA Ventures LLC, an affiliate of Reliance ADA Group Companies. Dr. Shah completed his post-doctoral fellowship in Infectious Diseases from Stanford University School of Medicine. He holds a Ph.D. in Microbiology from the University of Mississippi Medical Center and a M.B.A. in Finance from the Wharton School, University of Pennsylvania.

What is the salary of Preetam Shah?

As the Chief Financial Officer, Executive Vice President, e Treasurer of Brainstorm Cell Therapeutics, the total compensation of Preetam Shah at Brainstorm Cell Therapeutics is $646,892. There are 5 executives at Brainstorm Cell Therapeutics getting paid more, with Chaim Lebovits having the highest compensation of $1,639,680.

How old is Preetam Shah?

Preetam Shah is 47, he's been the Chief Financial Officer, Executive Vice President, e Treasurer of Brainstorm Cell Therapeutics since 2019. There are 12 older and 5 younger executives at Brainstorm Cell Therapeutics. The oldest executive at Brainstorm Cell Therapeutics, Inc. is Malcolm Taub, 74, who is the Independent Director.

What's Preetam Shah's mailing address?

Preetam's mailing address filed with the SEC is 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO, CA, 92121.

Insiders trading at Brainstorm Cell Therapeutics

Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over $1,899,994 worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth $1,535,874 . The most active insiders traders include Corp. Accbt, Mike Frankenberger, eInternational Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of $206,459. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth $22,050.

What does Brainstorm Cell Therapeutics do?

brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr

Complete history of Preetam Shah stock trades at Brainstorm Cell Therapeutics e Cidara Therapeutics Inc

Brainstorm Cell Therapeutics executives and stock owners

Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include:

• Chaim Lebovits,
  Chief Exec. Officer
• Chaim Lebovits,
  Chief Executive Officer
• Ralph Kern,
  President, Chief Medical Officer
• Dr. Ralph Z. Kern,
  Pres & Chief Medical Officer
• Dr. Stacy R. Lindborg Ph.D.,
  Exec. VP & Chief Devel. Officer
• Preetam Shah,
  Chief Financial Officer, Executive Vice President, Treasurer
• Irit Arbel,
  Vice Chairman of the Board
• Malcolm Taub,
  Independent Director
• Uri Yablonka,
  Executive Vice President, Chief Business Officer, Director
• June Almenoff,
  Independent Director
• Anthony Polverino,
  Independent Director
• Arturo Araya,
  Chief Commercial Officer
• Uri Yablonka,
  Exec. VP, Chief Bus. Officer, Sec. & Director
• Dr. Irit Arbel DSc, Ph.D.,
  Co-Founder & Independent Vice Chair of the Board
• Dr. Irit Arbel Ph.D., DSc,
  Co-Founder & Independent Vice Chair of the Board
• Sankesh Abbhi,
  Director
• Anthony Waclawski,
  Executive Vice President - Global Head of Regulatory Affairs
• Stacy Lindborg,
  Executive Vice President Head of Global Clinical Research
• David Setboun,
  Chief Operating Officer, Executive Vice President
• Jacob Frenkel,
  Chairman of the Board
• Antal Pearl-Lendner,
  VP & Chief Legal Counsel
• Alla Patlis CPA, M.B.A.,
  Controller & Interim CFO
• William K. White,
  Sr. VP & Head of Market Access and Pricing
• Dr. Daniel Offen,
  Chief Scientific Advisor
• Dr. Yael Gothelf,
  VP of Scientific & Regulatory Affairs
• Dr. David Setboun M.B.A., Pharm.D.,
  Exec. VP & COO
• Dr. Preetam Shah M.B.A., Ph.D.,
  Exec. VP, CFO & Treasurer
• Mordechai Friedman,
  Director
• International Holdings Ltd....,
  
• Alon Pinkas,
  Director
• Robert G L Shorr,
  Director
• Yoram Bibring,
  Chief Financial Officer
• Chen Schor,
  Director
• Eyal Rubin,
  CFO and Treasurer
• Nir Naor,
  Director
• Alla Patlis,
  See Remarks
• Anthony S. Fiorino,
  Chief Executive Officer
• Liat Sossover,
  Chief Financial Officer
• Avi Israeli,
  Director
• Adrian Harel,
  Acting Chief Executive Officer
• Corp. Accbt,
  10% owner
• Aviv University Economic Co...,
  10% owner
• Aviv University Tel,
  10% owner
• Abraham Efrati,
  Chief Executive Officer
• David Stolick,
  Chief Financial Officer
• At Tel Aviv University Ltd ...,
  10% owner
• Jonathan C Javitt,
  Director
• Beck Yaffa,
  President and CEO
• Moshe Lion,
  Director
• Michael D Greenfield,
  Director
• Yoram Drucker,
  Chief Operating Officer
• Mike Frankenberger,
  
• Kirk Taylor,
  Chief Medical Officer
• Hartoun Hartounian,
  EVP, Chief Operating Officer
• Ibrahim B. Dagher,
  Chief Medical Officer